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Background: In resource-limited settings, clinical parameters,
including body weight changes, are used to monitor clinical
response. Therefore, we studied body weight changes in patients
on antiretroviral treatment (ART) in different regions of the world.
Methods: Data were extracted from the “International Epidemio-
logic Databases to Evaluate AIDS,” a network of ART programmes
that prospectively collects routine clinical data. Adults on ART from
the Southern, East, West, and Central African and the Asia-Paciﬁc
regions were selected from the database if baseline data on body
weight, gender, ART regimen, and CD4 count were available. Body
weight change over the ﬁrst 2 years and the probability of body
weight loss in the second year were modeled using linear mixed
models and logistic regression, respectively.
Results: Data from 205,571 patients were analyzed. Mean
adjusted body weight change in the ﬁrst 12 months was higher in
patients started on tenofovir and/or efavirenz; in patients from
Central, West, and East Africa, in men, and in patients with
a poorer clinical status. In the second year of ART, it was greater
in patients initiated on tenofovir and/or nevirapine, and for
patients not on stavudine, in women, in Southern Africa and in
patients with a better clinical status at initiation. Stavudine in
the initial regimen was associated with a lower mean adjusted
body weight change and with weight loss in the second
treatment year.
Conclusions: Different ART regimens have different effects on
body weight change. Body weight loss after 1 year of treatment in
patients on stavudine might be associated with lipoatrophy.
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INTRODUCTION
Monitoring HIV-positive patients on antiretroviral
treatment (ART) remains a challenge in countries with limited
resources. In many of them, routine viral load and even CD4
lymphocyte count monitoring is not possible or available.1
Therefore, in these settings, clinical parameters, including
body weight changes, are used to monitor clinical response.2
Signiﬁcant body weight loss before the start of ART is
usually associated with advancing HIV disease and the
presence of opportunistic infections (in low-resource coun-
tries mainly tuberculosis).3 Short-term weight evolution is an
indicator of treatment success. Indeed, weight gain at 3
months was found to be strongly associated with survival4
and weight loss as early as 1–6 months after ART initiation
has been associated with a high risk of adverse outcomes.5–7
Previous studies mainly focused on early periods during ART
(generally less than 12 months).
The objective of our study was to describe body weight
changes and associations with those changes across regions of
the world among patients receiving up to 2 years of ART.
METHODS
Data were extracted from the “International Epidemiologic
Databases to Evaluate AIDS,” a large network of ART
programmes that prospectively collects routine clinical data
(IeDEA) (http://www.iedea.org/). Its aim is to collect baseline
and follow-up characteristics on HIV-positive patients initiating
ART worldwide.8 These characteristics include demographic
(age, gender, geographical region), clinical (weight, height,
pregnancies, morbidity, medication), and biological (CD4 count,
viral load) data. Adult patients (aged .18 years) on ART from
the Southern, East, West, and Central African regions and the
Asia-Paciﬁc region were selected from the database if baseline
data (within a 60-day window before start of ART) on body
weight, gender, ART regimen, and CD4 count were available.
Data for the study were collected from 140 sites, including 18
from Asia-Paciﬁc, 10 from Central-Africa, 10 from East-Africa,
87 from Southern Africa, and 15 fromWest Africa. HIV-positive
patients were included in this analysis if at ART initiation they
were ART naive and starting ﬁrst-line ART containing at least 3
different antiretroviral drugs. Pregnant women and patients on
investigational study drugs or on implausible regimens [regi-
mens containing the following combinations: zidovudine (AZT)
and stavudine (D4T), AZT and tenofovir (TDF), D4T and TDF,
and efavirenz (EFV) and nevirapine (NVP)] were excluded. All
patients who had at least 1 baseline weight measure were
included. Body weight change at time t is deﬁned as body
weight at time t minus body weight at ART initiation.
Statistical Analysis
The body mass index (BMI) was computed when body
weight and height were both available; its 24-month evolution
was graphically represented by region. As a signiﬁcant
proportion of patients had missing height, the main analytical
models were based on body weight instead of BMI to avoid
a selection bias. Individuals with complete and incomplete
BMI data were compared.
Model 1
Body weight change was modeled over the ﬁrst 2
years on ART using linear mixed models (LMMs) with no
intercept and 2 slopes; the ﬁrst slope over the ﬁrst year of
ART and the second slope over the second. To account for
intraindividual correlation, we added random effects on the
2 slopes with an unstructured variance–covariance matrix.
The LMMs were adjusted for geographical region, gender,
age, initial body weight, initial clinical stage, ﬁrst ART
regimen, initial hemoglobin, calendar year of ART initia-
tion, and initial CD4 count. The ﬁrst body weight change
slope was also adjusted for CD4 count changes between
month 0 and month 12 and the second slope was adjusted for
CD4 count change between 12 and 24 months. Moreover,
we let the association between D4T and body weight change
in the second year of ART to interact with baseline body
weight, region, gender, age at ART initiation, and baseline
CD4 count.
Model 2
This model studied risk factors for any weight loss
larger than 5% in the second year of ART by ﬁtting a multiple
logistic model with weight loss larger than 5% during the
second year as a binary outcome variable. Not all patients had
a weight measurement exactly at 1 year and 2 years after start
of ART treatment. Hence, we estimated the weight after the
ﬁrst year as the mean weight between 6 and 18 months and
the weight after the second year as the mean weight between
18 and 30 months.
To account for missing data, missing CD4 counts were
imputed using CD4 counts estimated with a predictive LMM,
adjusted for geographical region, gender, age, initial body
weight, clinical stage, ART, and initial hemoglobin.
RESULTS
Baseline Characteristics
Data from 212,795 patients were received from the
IeDEA regions. Reasons for exclusion of 7224 (3.4%) patients
were age under 18 years (n = 581) and implausible regimen (n
= 6643) leaving 205,571 patients for analysis [139,174 (67.7%)
from Southern Africa, 42,856 (20.8%) from East Africa,
17,202 (8.4%) from West Africa, 4700 (2.3%) from Central
Africa, and 1639 (0.8%) from Asia Paciﬁc] (see Table S1,
Supplemental Digital Content, http://links.lww.com/QAI/A690
for number of patients per country). Patient characteristics at
ART initiation by geographical region are described in Table 1.
Of the 205,571 patients included in the analysis of the ﬁrst year
of ART in 58,835 (28.6%) of them, only a weight measurement
at baseline was available. In the remaining patients, the median
number of weight measurements was 3 [interquartile range
(IQR), 2–4]. In the second year of ART, 104,744 patients had
at least 1 weight measurement. The median number of weight
measurements was 3 (IQR, 2–5). Patients initiated ART
between the years 2001 and 2010. The median (IQR) body
weight at ART initiation was 55 kg (48–62), 58 kg (52–65) at 6
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months, 60 kg (53–67) at 12 months, and 60 kg (54–68) at 24
months on ART (Table 1).
In all African regions, in contrast to the Asia-Paciﬁc
region, more women than men were enrolled in the cohorts
(Table 1). The median CD4 lymphocyte count at ART
initiation was 128 cells per microliter (IQR, 61–199) and
the median CD4 lymphocyte count was below 150 cells
per microliter in all cohorts. Most patients (57.7%) were in
WHO stage III or IV. Over half of regimens contained D4T
(n = 110,218, 53.6%) and roughly two-thirds contained
NVP (n = 132,088, 64.3%). Only in Southern Africa,
a relatively large proportion of patients (n = 43,515,
31.3%) were started on a TDF-containing regimen
(Table 1).
TABLE 1. Patient Characteristics at ART Initiation By Geographical Region (n = 205,571)
Asia Paciﬁc Central Africa East Africa Southern Africa West Africa Total
N (%) 1639 (0.8) 4700 (2.3) 42,856 (20.8) 139,174 (67.7) 17,202 (8.4) 205,571 (100)
Year of enrollment, range 1994–2010 1998–2010 2001–2009 1997–2010 1998–2009 1994–2010
Female (%) 588 (35.9) 3297 (70.1) 27,106 (63.2) 84,078 (60.4) 11,075 (64.4) 126,144 (61.4)
Age, median (IQR), yrs 34 (29–40) 38 (31–44) 37 (31–43) 35 (30–42) 36 (30–43) 35 (30–42)
Clinical stage (%)
WHO* I/II or CDC† $A 623 (38.0) 1413 (30.1) 13,263 (30.9) 45,194 (32.5) 6229 (36.2) 66,722 (32.5)
WHO III or CDC B 455 (27.8) 2615 (55.6) 18,383 (42.9) 68,408 (49.2) 7165 (41.7) 97,026 (47.2)
WHO IV or AIDS 561 (34.2) 652 (13.9) 6442 (15.0) 12,144 (8.7) 1795 (10.4) 21,594 (10.5)
Missing — 20 (0.4) 4768 (11.1) 13,428 (9.6) 2013 (11.7) 20,229 (9.8)
Year of ART initiation (%)
,2005 655 (40.0) 463 (9.9) 3070 (7.2) 7063 (5.1) 2741 (15.9) 13,992 (6.8)
2005–2006 567 (34.6) 870 (18.5) 19,321 (45.1) 35,178 (25.3) 8026 (46.7) 63,962 (31.1)
2007–2008 302 (18.4) 2094 (44.6) 20,085 (46.9) 53,071 (38.1) 6219 (36.2) 81,771 (39.8)
2009–2010 115 (7.0) 1273 (27.1) 380 (7.2) 43,862 (31.5) 216 (1.3) 45,846 (22.3)
First ART regimen, NRTI‡ (%)
AZT-based 598 (36.5) 1857 (39.5) 9688 (22.6) 28,177 (20.2) 5751 (33.4) 46,071 (22.4)
D4T-based 953 (58.1) 2752 (58.6) 32,928 (76.8) 64,265 (46.2) 9320 (54.2) 110,218 (53.6)
Tenofovir-based 56 (3.4) 66 (1.4) 225 (0.5) 43,515 (31.3) 1872 (10.9) 45,734 (22.2)
Other NRTIs§ 32 (2.0) 25 (0.5) 15 (0.0) 3217 (2.3) 259 (1.5) 3548 (1.7)
First ART# regimen, NNRTIk or
PI (%)
Efavirenz-based 487 (29.7) 715 (15.2) 8035 (18.7) 56,287 (40.4) 5514 (32.1) 71,038 (34.6)
Nevirapine-based 998 (60.9) 3933 (83.7) 34,724 (81.0) 82,314 (59.1) 10,119 (58.8) 132,088 (64.3)
PI# 154 (9.4) 52 (1.1) 97 (0.2) 573 (0.4) 1569 (9.1) 2445 (1.2)
CD4 count in cells/mL median
(IQR)
95 (33–188) 135 (65–204) 102 (40–175) 134 (67–202) 139 (60–223) 128 (61–199)
CD4 count missing (%) 341 (20.8) 1316 (28.0) 16,212 (37.8) 33,497 (24.1) 4312 (25.1) 55,678 (27.1)
Hemoglobin in g/dL median
(IQR¶)
12.1 (10.9–13.5) 10.2 (9.0–12.0) 11.2 (9.6–12.8) 10.9 (9.4–12.4) 10.2 (9.0–11.5) 10.9 (9.4–12.4)
Hemoglobin missing (%) 1314 (80.2) 3966 (84.4) 23,957 (55.9) 39,770 (28.6) 6203 (36.1) 75,310 (36.6)
Body weight in kg, median (IQR)
At ART initiation 54 (47–61) 56 (49–64) 54 (48–61) 55 (48–62) 56 (49–64) 55 (48–62)
At 6 mo 56 (50–65) 59 (53–68) 59 (53–65) 58 (52–65) 60 (53–68) 58 (52–65)
At 12 mo 57 (51–65) 61 (54–70) 60 (54–67) 59 (53–67) 62 (55–70) 60 (53–67)
At 24 mo 57 (50–64) 62 (54–71) 60 (54–67) 60 (54–68) 62 (55–71) 60 (54–68)
BMI in kg/m2, median (IQR)
At ART initiation 20.1 (18.1–22.5) 20.6 (18.2–23.5) 19.7 (17.6–21.9) 20.0 (17.9–22.5) 20.6 (18.2–23.4) 20.0 (17.9–22.5)
At 6 mo 21.3 (19.5–23.7) 22.0 (19.8–24.7) 21.2 (19.4–23.5) 21.4 (19.5–23.9) 22.1 (20.0–24.9) 21.4 (19.5–23.9)
At 12 mo 21.7 (19.8–23.8) 22.6 (20.3–25.7) 21.7 (19.7–24.1) 21.9 (19.8–24.6) 22.8 (20.4–25.6) 21.9 (19.9–24.6)
At 24 mo 21.6 (19.8–23.7) 23.0 (20.3–26.2) 21.7 (19.7–24.1) 22.1 (19.9–24.9) 23.0 (20.5–26.0) 22.1 (19.9–24.8)
International Epidemiologic Databases to Evaluate AIDS (IeDEA).
*WHO, World Health Organization.
†CDC, Centers for Disease Control.
‡NRTI, nucleoside/nucleotide reverse transcriptase inhibitor.
§Other NRTIs: didanosine, lamivudine, abacavir, and emtricitabine.
kNNRTI, nonnucleoside reverse transciptase inhibitor.
¶IQR, interquartile range.
#PI, protease inhibitor.
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BMI Evolution in Different Regions
BMI was computed for 165,804 individuals at baseline
(80.7% of the sample), 89,762 at M6 (43.7%), 70,285 at M12
(34.2%), 56,350 at M18 (27.4%), and 44,598 at M24
(21.7%). Individuals with complete and incomplete BMI data
were comparable at baseline (see Table S2, Supplemental
Digital Content, http://links.lww.com/QAI/A690).
BMI evolution within the ﬁrst 2 years of ART per
region is shown in Figure 1. For all regions, median BMI
increased in the ﬁrst 12 months after ART initiation, after
which it leveled off. Obesity (BMI.30 kg/m2) was present in
4402 patients (2.6%) at baseline and in 2644 (5.9%) after 2
years on ART. Of those patients with a BMI .30 kg/m2 after
2 years on ART, the BMI at baseline was #18 in 40 (1.5%),
between 18 and 25 in 705 (26.7%), between 25 and 30 in
1016 (38.4%), and .30 kg/m2 in 883 (33.4%).
Body Weight Change After ART Initiation
Adjusted body weight change slopes (kilograms per
year) for all patients from 0 to 12 months and from 12 to 24
months after ART initiation (model 1) are shown in Table 2,
taking as a reference in both analyses men aged ,30 years
who started ART in Southern Africa with TDF and EFV in
2009 or later, with an initial clinical stage WHO IV (or
AIDS), with a baseline CD4 count ,50 cells per microliter,
a CD4 cell count change between 0 and 149 at month 12 and
between 0 and 49 at month 24, hemoglobinemia ,7.5 g/dL,
and with an initial body weight of 55 kg.
Gender
In the ﬁrst year after ART initiation, the mean adjusted
body weight change was greater in men than in women
[20.29, 95% conﬁdence interval (CI): 20.38 to 20.20] but
in the second year, it was greater in women (1.22, 95% CI:
1.09 to 1.35).
ART Regimen
Patients initiating TDF-containing regimens had a high-
er mean adjusted body weight change in the ﬁrst 2 years
compared with patients who started on a regimen containing
AZT or other nucleoside/nucleotide reverse transcriptase
inhibitors. Patients started on a D4T-containing regimen had
a signiﬁcant lower mean adjusted body weight change in the
ﬁrst year on ART (20.16, 95% CI: 20.29 to 20.02). In the
second year on ART, there was no signiﬁcant difference in
mean adjusted body weight change between patients on D4T
and TDF. However, the effect on mean adjusted body weight
change in the second year of D4T in initial ART regimen
(Table 3) was more negative for patients from Eastern Africa
(20.77 kg/yr, 95% CI: 21.04 to 20.50), women (21.13
kg/yr, 95% CI: 21.29 to 20.96), elder patients (aged above
39 years) (21.16 kg/yr, 95% CI: 21.38 to 20.94), and
patients with a higher baseline body weight (20.34 kg/yr,
95% CI: 20.38 to 20.30, for every 5 kg more) and a CD4
cell count below 50 cells per microliter at baseline (compared
with a baseline CD4 count above 199 cells/mL) (Table 3).
Patients who started EFV had a higher mean adjusted
body weight change in the ﬁrst year than patients starting
NVP (20.69, 95% CI: 20.78 to 20.59) or a protease
inhibitor (PI) (21.41, 95% CI: 21.79 to 21.03) but patients
on a PI-based ART regimen had a higher median baseline
body weight: 57 kg (IQR, 49.6–66) versus 55 kg (IQR, 48–
62, P = 0.0000) compared with patients on a nonnucleoside
reverse transciptase inhibitor (NNRTI) regimen. There was no
FIGURE 1. Evolution of BMI within the
first 2 years of ART per region in the
study population (n = 165,804). Inter-
national Epidemiologic databases to
Evaluate AIDS (IeDEA).
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TABLE 2. Body Weight Change Slopes Within the First 24 Months After ART Initiation Modeled With the Adjusted LMM: Main
Effects (n = 205,571; Observations = 1,785,439)
From Month 0–12 From Month 12–24
Body Weight
Change, kg/yr 95% CI
Body Weight
Change, kg/yr 95% CI
Body weight change in reference group* 9.12 8.81 to 9.42 20.08 20.50 to 0.34
Gender (versus ref*)
Men Ref* — Ref* —
Women 20.29 20.38 to 20.20 1.22 1.09 to 1.35
NRTI† in ﬁrst ART regimen (versus ref*)
Tenofovir (TDF) Ref* — Ref* —
Tavudine (D4T) 20.16 20.29 to 20.02 0.01 20.30 to 0.32
Zidovudine (AZT) 20.29 20.43 to 20.15 20.45 20.61 to 20.28
Other NRTIs‡ 20.35 20.70 to 20.004 20.59 21.09 to 20.09
NNRTI§ or PIk in ﬁrst ART regimen (versus ref*)
Efavirenz (EFV) Ref* — Ref* —
Nevirapine (NVP) 20.69 20.78 to 20.59 0.34 0.23 to 0.44
PIs 21.41 21.79 to 21.03 20.25 20.62 to 0.12
Geographical region (versus ref*)
Southern Africa Ref* — Ref* —
Asia-Paciﬁc 20.41 20.81 to 20.01 20.68 21.23 to 20.12
Central Africa 1.85 1.54 to 2.16 20.63 21.19 to 20.07
East Africa 0.46 0.35 to 0.56 20.28 20.53 to 20.03
West Africa 1.56 1.40 to 1.71 20.08 20.30 to 0.15
Year of ART initiation (versus ref*)
2009–2010 Ref* — Ref* —
2007–2008 0.56 0.43 to 0.69 21.46 21.72 to 21.21
2005–2006 1.45 1.31 to 1.60 21.43 21.70 to 21.16
ART ,2005 1.56 1.36 to 1.75 20.93 21.22 to 20.64
Age at ART initiation (versus ref*), yrs
18–29 Ref* — Ref* —
30–34 0.41 0.30 to 0.53 0.15 20.03 to 0.33
35–39 0.64 0.52 to 0.76 0.28 0.09 to 0.47
.39 0.68 0.57 to 0.79 0.27 0.09 to 0.45
Baseline body weight (per 5 kg) (versus ref*)
55 kg Ref* — — —
For each 5 kg higher 20.90 20.92 to 20.88 0.29 0.26 to 0.32
Initial clinical stage (versus ref*)
AIDS or WHO IV Ref* — Ref* —
CDC B or WHO III 20.30 20.43 to 20.16 0.003 20.14 to 0.14
CDC A or WHO I/II 22.26 22.41 to 22.12 0.40 0.26 to 0.55
Clinical stage missing 20.49 20.68 to 20.30 0.08 20.12 to 0.28
Baseline CD4 count in cells/mL (versus ref*)
0–49 Ref* — Ref* —
50–199 22.04 22.15 to 21.92 0.08 20.11 to 0.28
.199 23.56 23.70 to 23.42 0.24 0.02 to 0.45
CD4 count change between M0 and M12 in cells/mL
(versus ref*)
,0 20.92 21.09 to 20.75 — —
0–149 Ref* — — —
150–249 0.56 0.47 to 0.65 — —
.249 1.43 1.33 to 1.54 — —
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signiﬁcant difference in CD4 cell count at baseline between
patients started on a PI compared with an NNRTI regimen
(117 versus 128 cells/mL, P = 0.3502).
In the second year, patients initiated on NVP had
a greater mean adjusted body weight change than patients
started on EFV (0.34, 95% CI: 0.23 to 0.44) (Table 2).
Geographical Regions
In the ﬁrst year, mean adjusted body weight change was
1.85 (95% CI: 1.54 to 2.16), 1.56 (95% CI: 1.40 to 1.71), and
0.46 kg/yr (95% CI: 0.35 to 0.56) higher in patients from the
Central, West, and East African regions, respectively, and
0.41 kg/yr (95% CI: 20.81 to 20.01) lower in the Asia-
Paciﬁc region compared with the Southern African region. In
the second year, mean adjusted body weight change was lower
in patients from the Central African (20.63, 95% CI: 21.19
to 20.07), East African (20.28, 95% CI: 20.53 to 20.03),
and Asia-Paciﬁc (20.68, 95% CI: 21.23 to 20.12) regions
compared with the Southern African region.
Clinical and Biological Status
The mean adjusted body weight change in the ﬁrst year
was higher in patients with a poorer clinical status, reﬂected by
higher WHO stage [WHO stage I/II: 22.26 (95% CI: 2.12 to
2.41) compared with WHO stage IV], lower baseline CD4
lymphocyte count [baseline CD4 cell count larger than 199:
23.56 (95% CI: 3.42 to 3.70) compared with baseline CD4
cell count 0–49 cells/mL], lower hemoglobin level [baseline
hemoglobin $10 g/dL: 22.17 (95% CI: 1.94 to 2.41)
compared with a hemoglobin ,7.5 g/dL] and lower initial
body weight [for every 5 kg higher 20.90 (95% CI: 20.92
to20.88)]. Furthermore, mean adjusted body weight change in
the ﬁrst year was higher in patients with a CD4 lymphocyte
count change of more than 249 cells per microliter [1.43 (95%
CI: 1.33 to 1.54)] compared with patients with a CD4 cell
count change between 0 and 149 cells per microliter. Contrary
to the ﬁrst year, the mean adjusted body weight change in
patients with a poorer clinical state (lower CD4 count, higher
WHO stage and lower adjusted body weight) at baseline was
lower than in patients with the better clinical state at baseline,
but patients with the highest CD4 cell count change (.99
cells/mL) between 12 and 24 months of treatment still had the
highest mean adjusted body weight change (0.44, 95% CI: 0.33
to 0.55, compared with 0–49 cells/mL CD4 cell count change).
Weight Loss in the Second Year of Treatment
In both the 130,427 patients in the 6–18-month period as
in the 84,394 patients in the 18–30-month period with at least 1
weight measurement, the median number of weight measure-
ments was 3 (IQR, 2–5). Between 12 and 24 months of ART
treatment, 45.8% of patients lost weight overall. The median
weight loss in this subgroup of patients was 2.0 kg (IQR, 1.0–
3.6). At 24 months of treatment, 68.7% of these patients lost
between 0% and 5% of their body weight at 12 months, 23.4%
between 5% and 10% and 7.9% lost more than 10% of their
body weight at 12 months. The median weight gained in the
subgroup of patients who gained weight in the second year of
therapy was 2.1 kg (IQR, 0.9–4.0). A higher probability for
weight loss larger than 5% between 12 and 24 months of
treatment (model 2, Table 4) was associated with the use of
D4T [adjusted odds ratio (aOR), 1.28; 95% CI: 1.19 to 1.39] or
other NRTIs (aOR, 1.54; 95% CI: 1.22 to 1.96) compared with
TDF and with PIs (aOR, 1.43; 95% CI: 1.19 to 1.72) or NVP
(aOR, 1.06; 95% CI: 1.01 to 1.12) compared with EFV in initial
ART regimen; with women (aOR, 1.48; 95% CI: 1.41 to 1.55)
TABLE 2. (Continued ) Body Weight Change Slopes Within the First 24 Months After ART Initiation Modeled With the Adjusted
LMM: Main Effects (n = 205,571; Observations = 1,785,439)
From Month 0–12 From Month 12–24
Body Weight
Change, kg/yr 95% CI
Body Weight
Change, kg/yr 95% CI
CD4 count change between M12 and M24 in cells/mL
(versus ref*)
,0 — — 20.16 20.27 to 20.04
0–49 — — Ref* —
50–99 — — 20.06 20.17 to 0.05
.99 — — 0.44 0.33 to 0.55
Baseline hemoglobin in g/dL (versus ref*)
,7.5 Ref* — Ref* —
7.5–10 20.84 21.08 to 20.60 0.28 0.04 to 0.52
$10 22.17 22.41 to 21.94 0.33 0.10 to 0.56
Missing 22.36 22.60 to 22.13 0.32 0.08 to 0.56
*Reference group: men aged ,30 years who started ART in Southern Africa with tenofovir and efavirenz in 2009 or later, with an initial clinical stage WHO IV (or AIDS), with
a baseline CD4 count ,50 cells per microliter, a CD4 count change = 0–149 at M12 and 0–49 at M24, hemoglobinemia ,7.5 g/dL and with an initial body weight = 55 kg.
†NRTI, nucleoside/nucleotide reverse transcriptase inhibitor.
‡Other NRTIs: didanosine, lamivudine, abacavir, and emtricitabine.
§NNRTI, nonnucleoside reverse transciptase inhibitor.
kPI, protease inhibitor.
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compared with men; with a higher baseline body weight (aOR,
1.05 per 5 kg; 95% CI: 1.04 to 1.06), with a CD4 count change
less than 0 in the second year (aOR, 1.11; 95% CI: 1.04 to
1.18), with a WHO stage IV and year of ART initiation before
2009 (Table 4). A lower probability of weight loss larger than
5% between 12 and 24 months of treatment was associated with
West African (aOR, 0.76; 95% CI: 0.69 to 0.82) and East
African (aOR, 0.91; 95% CI: 0.86 to 0.97) regions compared
with the Southern African region; age between 35 and 40 years
(aOR, 0.88; 95% CI: 0.82 to 0.94) compared with age younger
than 29 years and a baseline CD4 cell count above 199 cells
(aOR, 0.87; 95% CI: 0.81 to 0.94) (Table 4).
When comparing baseline characteristics between pa-
tients with complete data availability and patients where CD4
counts were imputed, results were similar (see Tables S3-S4,
Supplemental Digital Content, http://links.lww.com/QAI/A690).
DISCUSSION
Our study shows that persons with HIV infection
experienced the most weight gain during the ﬁrst year after
ART initiation and that the second year weight changes were
equally distributed between losses and gains. The study
showed that weight gain was more pronounced in patients
with a poorer clinical condition at the start of ART, reﬂected
by a low pretreatment CD4 cell count, a more advanced
WHO clinical stage, lower hemoglobin level, and lower
baseline body weight. This has also been reported pre-
viously.9,10 Hurley et al11 also reported that the lower the
BMI of patients was at start of ART, the higher the weight
gain was after 1 year of treatment in a single cohort in
South Africa.
Almost half of the patients lost weight in the second
year of treatment, with almost 8% of these patients losing
more than 10% of their weight at 12 months of treatment. It
might be due, among other reasons, to therapy failure,
opportunistic infection (tuberculosis), or intentional weight
loss (diet or exercise). A study from Rwanda also showed that
with D4T-based ART, a high proportion of patients had
a progressive decline of body weight in the second year of
treatment.12 There are not enough data available in our study
to fully explain this weight loss. There was however
a difference in total weight change after 2 years of treatment
according to the antiretroviral drugs in the initial regimen,
within the nucleoside/nucleotide reverse transcriptase inhib-
itor category the highest weight gain in patients on a TDF-
containing regimen. Certain patients on a D4T regimen had
a smaller weight gain or even lost weight after 1 year of ART.
This has also been observed in a study from Rwanda where
such weight loss was probably due to lipoatrophy, a conse-
quence of mitochondrial toxicity.13 In our analysis adjusted
for CD4 cell count change over the 12–24-month period, the
smaller weight gain in patients on a D4T-containing regimen
was still seen. Indeed, not only treatment failure but also
adverse events such as painful neuropathies can contribute to
weight loss. Others also showed that the impact of virological
failure on weight evolution during the second year of ART
was not signiﬁcant.11 Although lipoatrophy measurements
were not available in our database, our hypothesis is that this
D4T-related weight loss is indeed due to lipoatrophy. The
lower weight gain in patients on D4T was mainly seen in
patients from East-Africa, females, patients with a higher
baseline body weight, older patients, and patients with a CD4
cell count below 50 cells per microliter at baseline. This
corresponds to the ﬁndings of van Griensven et al,12 who
showed that being female, a longer duration of ART,
a baseline BMI $25 kg/m2, a D4T-based ART-regimen
(compared with an AZT-based regimen) but also (in contrast
to our ﬁndings) a baseline CD4 cell count $150 cells per
microliter, were signiﬁcantly associated with lipoatrophy. A
South African study showed that lactic acidosis, another
consequence of mitochondrial toxicity, was also associated
with female gender, increased BMI, and D4T therapy.14
Our study showed, in contrast to other studies,15 that
patients started on a PI-based therapy (mostly boosted
lopinavir) had on average a lower body weight increase than
patients starting on an NNRTI-based regimen. The group of
patients started on a PI-based ART regimen seems to be
a diverse group; in West Africa, patients on PI-based therapy
have a lower CD4 cell count than those not on PIs, whereas in
Asia-Paciﬁc, the opposite is the case. Patients who started
a PI-boosted ART regimen might have been patients pre-
viously exposed to an NNRTI, for example, because of
pregnancy (and therefore already had a higher CD4 cell
TABLE 3. Body Weight Change Slopes Within the First 24
Months After ART Initiation Modeled With the Adjusted LMM:
Interactions Terms With D4T in Second Year (n = 205,571;
Observations = 1,785,439)
Body Weight
Change, kg/yr 95% CI
Gender (versus ref*)
Men Ref* —
Women 21.13 21.29 to 20.96
Geographical region (versus ref*)
Southern Africa Ref* —
Asia-Paciﬁc 20.59 21.24 to 0.07
Central Africa 1.86 1.21 to 2.51
East Africa 20.77 21.04 to 20.50
West Africa 0.05 20.23 to 0.33
Age at ART initiation (versus ref*), yrs
18–29 Ref* —
30–34 20.60 20.83 to 20.37
35–39 20.78 21.02 to 20.54
.39 21.16 21.38 to 20.94
Baseline body weight (per 5 kg)
(versus ref*)
55 kg Ref* —
For each 5 kg higher 20.34 20.38 to 20.30
Baseline CD4 count in cells/mL
(versus ref*)
0–49 Ref* —
50–199 0.20 20.03 to 0.43
.199 0.50 0.24 to 0.77
*Reference group: men aged ,30 years who started ART in Southern Africa with
a baseline CD4 count ,50 cells per microliter and with an initial body weight = 55 kg.
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count), or were patients from more wealthy Asian countries
where PIs may be used as ﬁrst-line therapy and at higher CD4
count. Excluding from the analysis, patients with HIV-2
infection on PIs did not change the results.
Although weight gain is mostly regarded as being
beneﬁcial in patients with HIV, we have to take into account
the current obesity epidemics in several resource-limited
settings.16 Overweight and obesity are indeed important health
risk factors predisposing for cardiovascular and metabolic
diseases and certain cancer types.17 Overweight and obese
patients with HIV were found to have a higher prevalence of
multimorbidity than patients with normal or underweight.18
The strength of our study lies in its large number of
participants from various resource-limited countries. This is
a strong advantage to detect statistical signiﬁcant differences
between treatment regimens. However, it is unclear how
clinically signiﬁcant some of these differences are. Indeed,
our study had several limitations. HIV treatment centers
participating in the IeDEA network cannot be considered to
be representative of all the HIV treatment centers in the
regions included in the study. The majority of patients were
included in the Southern African region (67.7%) (with almost
75% of patients coming from Zambia) and only 0.80% from
the Asia-Paciﬁc region. We did however correct the outcomes
for region, but cannot prevent some bias of data. Moreover,
data were collected during routine care and therefore were not
of the same quality as data collected during clinical trials. Our
cohort data contained many missing variables and no
information was available on adherence to drugs, drug
switches or discontinuations, coinfections, lipodystrophy,
access to food programs, pregnancies during follow-up, and
number of patients who were lost to follow-up, transferred, or
who died. HIV RNA plasma viral load measurements were
available in a subgroup of patients. However, in some regions
of all measured viral loads, the majority (up to 96.1% in the
East African region) was 50 copies per milliliter or higher at
month 24 after initiation of ART. This suggests that viral load
measurements were only performed if there were clinical
clues of failure (or nonadherence).
TABLE 4. Adjusted Odds Ratio on Weight Loss $5% in the
Second Year of ART of Each Variable Compared With Its
Reference Level
Variables aOR 95% CI P
Body weight loss in reference group* 0.11 0.09 to 0.13 ,0.0001
Gender (versus ref*)
Men Ref* — —
Women 1.48 1.41 to 1.55 ,0.0001
NRTI† in ﬁrst ART regimen (versus
ref*) (P , 0.0001)
Tenofovir Ref* — —
Stavudine 1.28 1.19 to 1.39 ,0.0001
Zidovudin 0.97 0.89 to 1.05 0.420
Other NRTIs‡ 1.54 1.22 to 1.96 0.0004
NNRTI§ or PIk in ﬁrst ART regimen
(versus ref*) (P = 0.0005)
Efavirenz Ref* — —
Nevirapine 1.06 1.01 to 1.12 0.032
PI 1.43 1.19 to 1.72 0.0001
Geographical region (versus ref*)
(P # 0.0001)
Southern Africa Ref* — —
Asia-Paciﬁc 0.88 0.73 to 1.06 0.169
Central Africa 0.82 0.67 to 1.01 0.055
East Africa 0.91 0.86 to 0.97 0.001
West Africa 0.76 0.69 to 0.82 ,0.0001
Year of ART initiation (versus ref*)
(P , 0.0001)
,2005 1.23 1.03 to 1.46 0.021
2005–2006 1.38 1.18 to 1.63 ,0.0001
2007–2008 1.30 1.11 to 1.52 0.001
2009–2010 Ref* — —
Age at ART initiation (versus ref*)
(P = 0.0002), yrs
18–29 Ref* — —
30–35 0.96 0.91 to 1.02 0.220
35–40 0.88 0.82 to 0.94 0.0001
$40 0.99 0.94 to 1.05 0.791
Baseline body weight (per 5 kg)
(versus ref*)
55 kg Ref* — —
For each 5 kg higher 1.05 1.04 to 1.06 ,0.0001
Initial clinical stage (versus ref*)
AIDS or WHO IV Ref* — —
CDC B or WHO III 0.84 0.78 to 0.90 ,0.0001
CDC A or WHO I/II 0.93 0.87 to 1.00 0.047
Clinical stage missing 1.00 0.91 to 1.10 0.982
Baseline CD4 count in cells/mL
(versus ref*)
0–49 Ref* — —
50–199 0.96 0.90 to 1.02 0.159
.199 0.87 0.81 to 0.94 0.0002
CD4 count change between M12 and
M24 in cells/mL (versus ref*)
,0 1.11 1.04 to 1.18 0.002
0–49 Ref* — —
50–99 1.03 0.97 to 1.10 0.322
.99 0.98 0.92 to 1.04 0.546
TABLE 4. (Continued ) Adjusted Odds Ratio on Weight Loss
$5% in the Second Year of ART of Each Variable Compared
With Its Reference Level
Variables aOR 95% CI P
Baseline hemoglobin in g/dL
(versus ref*)
,7.5 Ref*‡ — —
7.5–10 0.93 0.83 to 1.04 0.212
$10 0.91 0.81 to 1.02 0.095
Missing 0.92 0.82 to 1.04 0.180
*The reference group: baseline body weight = 55 kg, TDF, EFV, region = Southern
Africa, men, WHO IV, start year 2009–2010, age: 18–30, baseline CD4 cell count ,50,
CD4 change during second year 0–50, hb ,7.5.
†NRTI, nucleoside/nucleotide reverse transcriptase inhibitor.
‡Other NRTIs: didanosine, lamivudine, abacavir, and emtricitabine.
§NNRTI, nonnucleoside reverse transciptase inhibitor.
kPI, protease inhibitor.
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In conclusion, body weight increase, particularly in the
ﬁrst year of ART, is correlated with CD4 count increase and
therefore may suggest that a patient is on an effective ART
regimen. After the ﬁrst year of ART, the body weight increase
is leveling off, and in certain patients on a D4T regimen, body
weight may even decrease because of lipoatrophy. Hopefully,
with the 2013 WHO treatment guidelines, where D4T is not
advised as the preferred ﬁrst-line therapy, and with patients
starting ART much earlier, there will be less thymidine-related
side effects.14 Weight and ideally BMI measurements may then
become more meaningful to monitor treatment response from
a clinical standpoint and basic program success indicator.
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